c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C

Related Experiment Video

Updated: Jun 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pablo Lopez-Bergami1, Hyungsoo Kim, Antimone Dewing

  • 1Signal Transduction Program, The Burnham Institute for Medical Research, La Jolla, California 92037, USA.

The Journal of Biological Chemistry
|November 14, 2009
PubMed

Insights

c-Jun transcription factor regulates phosphoinositide-dependent kinase 1 (PDK1) in melanoma, impacting Akt and protein kinase C (PKC) activity. This finding reveals new mechanisms for melanoma growth and oncogenic activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Mutations in N-RAS and B-RAF drive melanoma by activating the MAPK/ERK pathway.
  • ERK signaling increases c-Jun transcription factor activity, linking ERK and JNK cascades.

Purpose of the Study:

  • To investigate the role of c-Jun in regulating phosphoinositide-dependent kinase 1 (PDK1) expression and its downstream effects in melanoma.
  • To elucidate the mechanisms by which c-Jun contributes to melanoma growth and oncogenesis.

Main Methods:

  • Investigated the transcriptional regulation of PDK1 by c-Jun in melanoma cell lines.
  • Assessed the impact of c-Jun inhibition on Akt and protein kinase C (PKC) activity.
  • Utilized exogenous PDK1 to restore signaling pathways.
  • Evaluated the role of c-Jun/PDK1 axis in melanoma tumor formation in mice.

Main Results:

  • c-Jun directly regulates PDK1 transcription, influencing Akt and PKC activity.
  • Inhibition of c-Jun decreased PDK1 expression and attenuated Akt/PKC activity.
  • Restoration of PDK1 levels rescued the observed signaling changes.
  • c-Jun-mediated regulation of PDK1 contributed to melanoma cell growth and tumor formation in vivo.
  • Elevated c-Jun levels in melanoma correlated with increased PDK1 and phosphorylated Akt/PKC.

Conclusions:

  • c-Jun is a key transcriptional regulator of PDK1 in melanoma.
  • The c-Jun/PDK1 axis is crucial for melanoma cell proliferation and tumorigenesis.
  • This study identifies novel mechanisms underlying oncogenic signaling in melanoma, involving c-Jun, PDK1, Akt, and PKC.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...